Cited by 153

The translational biology of remyelination: past, present, and future

Franklin, Robin J. M., Gallo, Vittorio·2014·Glia

Abstract

Amongst neurological diseases, multiple sclerosis (MS) presents an attractive target for regenerative medicine. This is because the primary pathology, the loss of myelin‐forming oligodendrocytes, can be followed by a spontaneous and efficient regenerative process called remyelination. While cell transplantation approaches have been explored as a means of replacing lost oligodendrocytes, more recently therapeutic approaches that target the endogenous regenerative process have been favored. This is in large part due to our increasing understanding of (1) the cell types within the adult brain that are able to generate new oligodendrocytes, (2) the mechanisms and pathways by which this achieved, and (3) an emerging awareness of the reasons why remyelination efficiency eventually fails. Here we review some of these advances and also highlight areas where questions remain to be answered in both the biology and translational potential of this important regenerative process. GLIA 2014;62:1905–1915

Integrity signals

Registry

Crossref · 10.1002/glia.22622

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Functional recovery in MS patients will likely hinge on therapies that promote myelin regeneration.

    “Functional recovery in MS patients will likely hinge on the therapies that promote myelin regeneration (Deshmukh et al., 2013; Franklin and Gallo, 2014).”

    From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Franklin and Gallo, 2014

  • A failure in myelin repair after oligodendrocyte damage contributes to persistence of demyelination in multiple sclerosis and leukodystrophies.

    “A failure in myelin repair after OL damage contributes to persistence of demyelination in debilitating diseases such as multiple sclerosis (MS) and leukodystrophies (Franklin and Gallo, 2014).”

    From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Franklin and Gallo, 2014

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Franklin, R. J. M., & Gallo, V.
Affiliations
  • Wellcome Trust‐MRC Cambridge Stem Cell Institute and Department of Veterinary Medicine University of Cambridge Cambridge CB3 0ES United Kingdom
  • Center for Neuroscience Research, Children's National Medical Center Washington DC
Venue
Glia
Publisher
Wiley
Published
2014-01-20
Volume
62
Issue
11
Pages
1905-1915
ISSN
  • 0894-1491
  • 1098-1136
Cited by
153
References
16
Language
en
Funders
  • NIH (R01NS045702, R01NS056427)
  • National Multiple Sclerosis Society (RG 4019)
  • UK Multiple Sclerosis Society

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review